In breast cancer, Ou et al. reported MALAT1 was upregulated in triple-negative breast cancer and associated with clinical clinicopathological parameters (tumor size, LNMET, and TNM stage) [40]. Here, MALAT1 is linked to triple-negative breast carcinoma.